2017 Q1 Form 10-Q Financial Statement
#000156459017012372 Filed on June 09, 2017
Income Statement
| Concept | 2017 Q1 | 2016 Q1 |
|---|---|---|
| Revenue | $11.58M | $6.562M |
| YoY Change | 76.53% | -9.06% |
| Cost Of Revenue | $3.057M | $2.772M |
| YoY Change | 10.28% | 2.25% |
| Gross Profit | $8.527M | $3.790M |
| YoY Change | 124.99% | -15.87% |
| Gross Profit Margin | 73.61% | 57.76% |
| Selling, General & Admin | $9.724M | $7.413M |
| YoY Change | 31.17% | 56.79% |
| % of Gross Profit | 114.04% | 195.59% |
| Research & Development | $3.283M | $3.159M |
| YoY Change | 3.93% | 122.31% |
| % of Gross Profit | 38.5% | 83.35% |
| Depreciation & Amortization | $930.0K | $261.0K |
| YoY Change | 256.32% | 58.18% |
| % of Gross Profit | 10.91% | 6.89% |
| Operating Expenses | $20.13M | $13.13M |
| YoY Change | 53.29% | 52.56% |
| Operating Profit | -$8.544M | -$6.569M |
| YoY Change | 30.07% | 372.25% |
| Interest Expense | -$790.0K | $266.0K |
| YoY Change | -396.99% | -67.84% |
| % of Operating Profit | ||
| Other Income/Expense, Net | -$686.0K | -$2.917M |
| YoY Change | -76.48% | 5301.85% |
| Pretax Income | -$5.892M | -$9.752M |
| YoY Change | -39.58% | 329.6% |
| Income Tax | -$283.0K | $0.00 |
| % Of Pretax Income | ||
| Net Earnings | -$5.562M | -$9.752M |
| YoY Change | -42.97% | 329.23% |
| Net Earnings / Revenue | -48.01% | -148.61% |
| Basic Earnings Per Share | -$0.26 | -$0.81 |
| Diluted Earnings Per Share | -$0.26 | -$0.81 |
| COMMON SHARES | ||
| Basic Shares Outstanding | 21.34M | 11.97M |
| Diluted Shares Outstanding | 21.34M | 11.97M |
Balance Sheet
| Concept | 2017 Q1 | 2016 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $12.20M | $23.80M |
| YoY Change | -48.74% | -38.97% |
| Cash & Equivalents | $21.74M | $23.75M |
| Short-Term Investments | ||
| Other Short-Term Assets | $1.500M | $800.0K |
| YoY Change | 87.5% | 14.29% |
| Inventory | $6.000M | $600.0K |
| Prepaid Expenses | ||
| Receivables | $3.400M | $2.500M |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $23.10M | $27.70M |
| YoY Change | -16.61% | -34.52% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $2.800M | $2.300M |
| YoY Change | 21.74% | 5.8% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $9.600M | $20.00K |
| YoY Change | 47900.0% | |
| Total Long-Term Assets | $57.22M | $21.13M |
| YoY Change | 170.76% | 0.75% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $23.10M | $27.70M |
| Total Long-Term Assets | $57.22M | $21.13M |
| Total Assets | $80.32M | $48.83M |
| YoY Change | 64.48% | -22.83% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $3.500M | $2.536M |
| YoY Change | 38.01% | 84.97% |
| Accrued Expenses | $9.100M | $7.100M |
| YoY Change | 28.17% | 108.82% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | $32.40M | $4.400M |
| YoY Change | 636.36% | 316.67% |
| Total Short-Term Liabilities | $53.00M | $14.20M |
| YoY Change | 273.24% | 126.29% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $0.00 | $11.37M |
| YoY Change | -100.0% | -22.18% |
| Other Long-Term Liabilities | $6.500M | $2.800M |
| YoY Change | 132.14% | 9900.0% |
| Total Long-Term Liabilities | $0.00 | $11.37M |
| YoY Change | -100.0% | -22.33% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $53.00M | $14.20M |
| Total Long-Term Liabilities | $0.00 | $11.37M |
| Total Liabilities | $65.70M | $28.37M |
| YoY Change | 131.55% | 19.17% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$182.8M | |
| YoY Change | 13.11% | |
| Common Stock | $12.00K | |
| YoY Change | 0.0% | |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $14.60M | $20.46M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $80.30M | $48.83M |
| YoY Change | 64.43% | -22.83% |
Cashflow Statement
| Concept | 2017 Q1 | 2016 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$5.562M | -$9.752M |
| YoY Change | -42.97% | 329.23% |
| Depreciation, Depletion And Amortization | $930.0K | $261.0K |
| YoY Change | 256.32% | 58.18% |
| Cash From Operating Activities | -$6.740M | -$6.190M |
| YoY Change | 8.89% | 512.87% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $68.00K | $109.0K |
| YoY Change | -37.61% | -70.05% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $0.00 | |
| YoY Change | ||
| Cash From Investing Activities | -$70.00K | -$110.0K |
| YoY Change | -36.36% | -69.44% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 11.13M | 170.0K |
| YoY Change | 6447.06% | -95.67% |
| NET CHANGE | ||
| Cash From Operating Activities | -6.740M | -6.190M |
| Cash From Investing Activities | -70.00K | -110.0K |
| Cash From Financing Activities | 11.13M | 170.0K |
| Net Change In Cash | 4.339M | -6.130M |
| YoY Change | -170.78% | -339.45% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$6.740M | -$6.190M |
| Capital Expenditures | $68.00K | $109.0K |
| Free Cash Flow | -$6.808M | -$6.299M |
| YoY Change | 8.08% | 358.44% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2017Q1 | cdna |
Business Acquisition Deferred Payment Consideration With Interest Accretion
BusinessAcquisitionDeferredPaymentConsiderationWithInterestAccretion
|
6463000 | |
| CY2017Q1 | us-gaap |
Revenues
Revenues
|
11584000 | |
| CY2017Q1 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
-221000 | |
| CY2016Q1 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
-213000 | |
| CY2016Q1 | us-gaap |
Revenues
Revenues
|
6562000 | |
| CY2017Q1 | us-gaap |
Cost Of Services
CostOfServices
|
3057000 | |
| CY2016Q1 | us-gaap |
Cost Of Services
CostOfServices
|
2772000 | |
| CY2017Q1 | us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
2327000 | |
| CY2016Q1 | us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
0 | |
| CY2017Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
3283000 | |
| CY2016Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
3159000 | |
| CY2017Q1 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
3222000 | |
| CY2016Q1 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
1737000 | |
| CY2017Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
6502000 | |
| CY2016Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
5676000 | |
| CY2017Q1 | us-gaap |
Goodwill Impairment Loss
GoodwillImpairmentLoss
|
1958000 | |
| CY2016Q1 | us-gaap |
Goodwill Impairment Loss
GoodwillImpairmentLoss
|
0 | |
| CY2017Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
20128000 | |
| CY2016Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
13131000 | |
| CY2017Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-8544000 | |
| CY2016Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-6569000 | |
| CY2017Q1 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
-790000 | |
| CY2016Q1 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
-266000 | |
| CY2017Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-686000 | |
| CY2016Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-2917000 | |
| CY2017Q1 | us-gaap |
Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
|
4128000 | |
| CY2016Q1 | us-gaap |
Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
|
0 | |
| CY2017Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-5892000 | |
| CY2016Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-9752000 | |
| CY2017Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-283000 | |
| CY2016Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | |
| CY2017Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-5609000 | |
| CY2016Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-9752000 | |
| CY2017Q1 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-47000 | |
| CY2016Q1 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
0 | |
| CY2017Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-5562000 | |
| CY2016Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-9752000 | |
| CY2017Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.26 | |
| CY2016Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.81 | |
| CY2017Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.26 | |
| CY2016Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.81 | |
| CY2017Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
21343782 | |
| CY2016Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
11969714 | |
| CY2017Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
21343782 | |
| CY2016Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
11969714 | |
| CY2017Q1 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
264000 | |
| CY2016Q1 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
0 | |
| CY2017Q1 | us-gaap |
Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
|
-5345000 | |
| CY2016Q1 | us-gaap |
Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
|
-9752000 | |
| CY2017Q1 | us-gaap |
Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
|
-52000 | |
| CY2016Q1 | us-gaap |
Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
|
0 | |
| CY2017Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-5293000 | |
| CY2016Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-9752000 | |
| CY2017Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
934000 | |
| CY2016Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
261000 | |
| CY2017Q1 | us-gaap |
Cost Of Goods Sold Depreciation
CostOfGoodsSoldDepreciation
|
32000 | |
| CY2016Q1 | us-gaap |
Cost Of Goods Sold Depreciation
CostOfGoodsSoldDepreciation
|
0 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Royalties Payable
IncreaseDecreaseInRoyaltiesPayable
|
-10000 | |
| CY2016Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
109000 | |
| CY2017Q1 | cdna |
Amortization Of Deferred Revenue
AmortizationOfDeferredRevenue
|
2000 | |
| CY2016Q1 | cdna |
Amortization Of Deferred Revenue
AmortizationOfDeferredRevenue
|
16000 | |
| CY2017Q1 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
627000 | |
| CY2016Q1 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
41000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
576000 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
145000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-470000 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-171000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
|
245000 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
|
-563000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
382000 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
820000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
|
-865000 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
|
-758000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Royalties Payable
IncreaseDecreaseInRoyaltiesPayable
|
24000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
|
358000 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
|
2400000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
|
271000 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
|
0 | |
| CY2017Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-6741000 | |
| CY2016Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-6192000 | |
| CY2017Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
68000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
|
36000 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
|
0 | |
| CY2017Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-104000 | |
| CY2016Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-109000 | |
| CY2017Q1 | us-gaap |
Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
|
24002000 | |
| CY2017Q1 | us-gaap |
Proceeds From Repayments Of Restricted Cash Financing Activities
ProceedsFromRepaymentsOfRestrictedCashFinancingActivities
|
-9375000 | |
| CY2016Q1 | us-gaap |
Proceeds From Repayments Of Restricted Cash Financing Activities
ProceedsFromRepaymentsOfRestrictedCashFinancingActivities
|
0 | |
| CY2017Q1 | us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
44000 | |
| CY2016Q1 | us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
175000 | |
| CY2017Q1 | us-gaap |
Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
|
12915000 | |
| CY2016Q1 | us-gaap |
Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
|
16000 | |
| CY2016Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
6000 | |
| CY2017Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
1756000 | |
| CY2016Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
165000 | |
| CY2017Q1 | us-gaap |
Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
|
18000 | |
| CY2016Q1 | us-gaap |
Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
|
0 | |
| CY2017Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-5071000 | |
| CY2016Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-6136000 | |
| CY2015Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
29888000 | |
| CY2016Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
23752000 | |
| CY2017Q1 | cdna |
Business Acquisition Deferred Payment Consideration
BusinessAcquisitionDeferredPaymentConsideration
|
1018000 | |
| CY2017Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in the unaudited condensed consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to (i) revenue recognition, (ii) the differences between amounts billed and estimated receipts from payers, (iii) the determination of the accruals for clinical studies, (iv) the determination of refunds to be requested by third-party payers, (v) the fair value of assets and liabilities, including from acquisitions, (vi) inventory valuation, (vii) the valuation of warrants, Series A Preferred, and common stock issued in the Private Placement and Subsequent Financing, (viii) the fair value of contingent consideration in a business acquisition, (ix) the fair value of embedded derivatives, (x) measurement of stock-based compensation expense, (xi) the determination of the valuation allowance and estimated tax benefit associated with deferred tax assets and net deferred tax liability, (xii) any impairment of long-lived assets, including in-process technology and goodwill, and (xiii) legal contingencies. Actual results could differ from those estimates.</p></div> | |
| CY2017Q1 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentrations of Credit Risk and Other Risks and Uncertainties</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and accounts receivable. The Company’s policy is to invest its cash and cash equivalents in money market funds, obligations of U.S. government agencies and government-sponsored entities, commercial paper and various bank deposit accounts. The counterparties to the agreements relating to the Company’s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent of amounts recorded on the balance sheets which may be in excess of insured limits.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is also subject to credit risk from its accounts receivable, which are derived from revenue earned from AlloMap tests provided for patients located in the U.S. and billed to various third-party payers, and sales of Olerup products to distributors, strategic partners and end customers in Europe, Middle East and Africa, the U.S., Latin America and other geographic regions. The Company has not experienced any significant credit losses and does not generally require collateral on receivables. <font style="color:#000000;"> </font>For the three months ended March 31, 2017 and 2016, approximately 28% and 47%, respectively, of total revenue was derived from Medicare. No other payers represented more than 10% of total revenue for these periods. At March 31, 2017, Medicare accounted for approximately 24% of accounts receivable. At December 31, 2016, Medicare accounted for approximately 27% of accounts receivable. No other payers or customers represented more than 10% of accounts receivable at either March 31, 2017 or December 31, 2016. </p></div> | |
| CY2017Q1 | us-gaap |
Revenue Recognition Multiple Element Arrangements
RevenueRecognitionMultipleElementArrangements
|
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Collaboration, License and Other Revenue</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company generates revenue from collaboration and license agreements. Collaboration and license agreements may include non-refundable upfront payments, partial or complete reimbursement of research and development costs, contingent payments based on the occurrence of specified events under the agreements, license fees and royalties on sales of products or product candidates if they are successfully commercialized. The Company’s performance obligations under the collaborations may include the transfer of intellectual property rights in the form of licenses, obligations to provide research and development services and obligations to participate on certain development committees with the collaboration partners. The Company makes judgments that affect the periods over which it recognizes revenue. The Company periodically reviews its estimated periods of performance based on the progress under each arrangement and accounts for the impact of any change in estimated periods of performance on a prospective basis. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes contingent consideration received from the achievement of a substantive milestone in its entirety in the period in which the milestone is achieved, which the Company believes is consistent with the substance of its performance under its various license and collaboration agreements. The Company did not recognize any revenue connected with milestones during the three months ended March 31, 2017 or 2016.</p></div> | |
| CY2016Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-9752000 | |
| CY2017Q1 | us-gaap |
Advertising Cost Policy Expensed Advertising Cost
AdvertisingCostPolicyExpensedAdvertisingCost
|
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Advertising Expenses</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All advertising costs are expensed as incurred. Advertising expenses were insignificant during all of the periods presented. </p></div> | |
| CY2017Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-5562000 | |
| CY2017Q1 | us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
2 | |
| CY2017Q1 | us-gaap |
Debt And Capital Lease Obligations
DebtAndCapitalLeaseObligations
|
32400000 | |
| CY2017Q1 | us-gaap |
Additional Cash And Cash Equivalent Related Text
AdditionalCashAndCashEquivalentRelatedText
|
Cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less from the date of purchase. | |
| CY2017Q1 | us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
0 | |
| CY2017Q1 | us-gaap |
Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
|
0 | |
| CY2016Q1 | us-gaap |
Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
|
0 | |
| CY2017Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
12924357 | |
| CY2016Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
2340464 | |
| CY2016Q2 | cdna |
Preferred Stock Issued Shares Private Placement
PreferredStockIssuedSharesPrivatePlacement
|
4630145 | |
| CY2016Q2 | cdna |
Preferred Stock Issued Shares Subsequent Financing
PreferredStockIssuedSharesSubsequentFinancing
|
4630145 | |
| CY2017Q1 | cdna |
Fair Value Measurements Inter Transfers Between Levels
FairValueMeasurementsInterTransfersBetweenLevels
|
0 | |
| CY2016 | cdna |
Fair Value Measurements Inter Transfers Between Levels
FairValueMeasurementsInterTransfersBetweenLevels
|
0 | |
| CY2016Q4 | us-gaap |
Goodwill Gross
GoodwillGross
|
26860000 | |
| CY2016Q4 | us-gaap |
Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
|
13021000 | |
| CY2017Q1 | us-gaap |
Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
|
85000 | |
| CY2017Q1 | us-gaap |
Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
|
39000 | |
| CY2017Q1 | us-gaap |
Goodwill Gross
GoodwillGross
|
26984000 | |
| CY2017Q1 | us-gaap |
Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
|
14979000 | |
| CY2017Q1 | us-gaap |
Number Of Reporting Units
NumberOfReportingUnits
|
2 | |
| CY2017Q1 | us-gaap |
New Date Of Annual Goodwill Impairment Test
NewDateOfAnnualGoodwillImpairmentTest
|
On January 1, 2017, the Company adopted ASU 2017-04, which eliminated the Step 2 requirement of the goodwill impairment test. Instead, the goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount. The new standard simplifies how an entity is required to test goodwill for impairment and reduces the cost and complexity of evaluating goodwill for impairment. In the three months ended March 31, 2017, the Company determined that the decrease in its market capitalization constituted an indicator of impairment and therefore a goodwill impairment test was completed as of March 31, 2017. | |
| CY2017Q1 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
31225000 | |
| CY2017Q1 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
2197000 | |
| CY2017Q1 | cdna |
Finite Lived Intangible Foreign Currency Translation
FiniteLivedIntangibleForeignCurrencyTranslation
|
2758000 | |
| CY2017Q1 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
26270000 | |
| CY2017Q1 | us-gaap |
Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
|
37875000 | |
| CY2017Q1 | cdna |
Intangible Assets Excluding Goodwill Accumulated Amortization
IntangibleAssetsExcludingGoodwillAccumulatedAmortization
|
2197000 | |
| CY2017Q1 | cdna |
Intangible Assets Excluding Goodwill Foreign Currency Translation Gain Loss
IntangibleAssetsExcludingGoodwillForeignCurrencyTranslationGainLoss
|
2758000 | |
| CY2017Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
600000 | |
| CY2016Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
0 | |
| CY2017Q1 | cdna |
Indefinite Lived Intangible Assets Excluding Goodwill Gross
IndefiniteLivedIntangibleAssetsExcludingGoodwillGross
|
6700000 | |
| CY2017Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
|
1734000 | |
| CY2017Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
|
2313000 | |
| CY2017Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
|
2313000 | |
| CY2017Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
|
2313000 | |
| CY2017Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
|
2313000 | |
| CY2017Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
|
2313000 | |
| CY2017Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
|
12971000 | |
| CY2017Q1 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
3338000 | |
| CY2016Q4 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
4199000 | |
| CY2017Q1 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
1745000 | |
| CY2016Q4 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
159000 | |
| CY2017Q1 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
965000 | |
| CY2016Q4 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
1103000 | |
| CY2017Q1 | cdna |
Accrued Clinical And Cost Of Other Studies Current
AccruedClinicalAndCostOfOtherStudiesCurrent
|
1456000 | |
| CY2016Q4 | cdna |
Accrued Clinical And Cost Of Other Studies Current
AccruedClinicalAndCostOfOtherStudiesCurrent
|
1375000 | |
| CY2017Q1 | cdna |
Accrued Tax Audit And Compliance Related Fees Current
AccruedTaxAuditAndComplianceRelatedFeesCurrent
|
1323000 | |
| CY2016Q4 | cdna |
Accrued Tax Audit And Compliance Related Fees Current
AccruedTaxAuditAndComplianceRelatedFeesCurrent
|
275000 | |
| CY2017Q1 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
866000 | |
| CY2016Q4 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
862000 | |
| CY2017Q1 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
299000 | |
| CY2016Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
345000 | |
| CY2017Q1 | cdna |
Accrued Debt Financing Fees Current
AccruedDebtFinancingFeesCurrent
|
0 | |
| CY2016Q4 | cdna |
Accrued Debt Financing Fees Current
AccruedDebtFinancingFeesCurrent
|
600000 | |
| CY2017Q1 | cdna |
Accrued Sample Processing Fees
AccruedSampleProcessingFees
|
578000 | |
| CY2016Q4 | cdna |
Accrued Sample Processing Fees
AccruedSampleProcessingFees
|
524000 | |
| CY2017Q1 | us-gaap |
Customer Refund Liability Current
CustomerRefundLiabilityCurrent
|
225000 | |
| CY2016Q4 | us-gaap |
Customer Refund Liability Current
CustomerRefundLiabilityCurrent
|
281000 | |
| CY2017Q1 | cdna |
Accrued Software Implementation Costs
AccruedSoftwareImplementationCosts
|
130000 | |
| CY2016Q4 | cdna |
Accrued Software Implementation Costs
AccruedSoftwareImplementationCosts
|
176000 | |
| CY2017Q1 | us-gaap |
Deferred Rent Credit Current
DeferredRentCreditCurrent
|
383000 | |
| CY2016Q4 | us-gaap |
Deferred Rent Credit Current
DeferredRentCreditCurrent
|
374000 | |
| CY2017Q1 | us-gaap |
Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
|
43000 | |
| CY2016Q4 | us-gaap |
Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
|
68000 | |
| CY2017Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
540000 | |
| CY2016Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
440000 | |
| CY2017Q1 | us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
400000 | |
| CY2016Q1 | us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
300000 | |
| CY2017Q1 | us-gaap |
Capital Leases Future Minimum Payments Remainder Of Fiscal Year
CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear
|
39000 | |
| CY2017Q1 | us-gaap |
Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
|
24000 | |
| CY2017Q1 | us-gaap |
Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
|
5000 | |
| CY2017Q1 | us-gaap |
Capital Leases Future Minimum Payments Due In Four Years
CapitalLeasesFutureMinimumPaymentsDueInFourYears
|
0 | |
| CY2017Q1 | us-gaap |
Capital Leases Future Minimum Payments Due In Five Years
CapitalLeasesFutureMinimumPaymentsDueInFiveYears
|
0 | |
| CY2017Q1 | us-gaap |
Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
|
68000 | |
| CY2017Q1 | us-gaap |
Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
|
1615000 | |
| CY2017Q1 | us-gaap |
Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
2060000 | |
| CY2017Q1 | us-gaap |
Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
|
2017000 | |
| CY2017Q1 | us-gaap |
Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
|
1994000 | |
| CY2017Q1 | us-gaap |
Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
|
1000 | |
| CY2017Q1 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
7687000 | |
| CY2016Q3 | us-gaap |
Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
|
1300000 | |
| CY2016Q4 | us-gaap |
Loss Contingency Loss In Period
LossContingencyLossInPeriod
|
1000000 | |
| CY2016Q4 | us-gaap |
Loss Contingency Loss In Period
LossContingencyLossInPeriod
|
100000 | |
| CY2017Q1 | us-gaap |
Loss Contingency Accrual Payments
LossContingencyAccrualPayments
|
1000000 | |
| CY2017Q1 | us-gaap |
Loss Contingency Accrual Payments
LossContingencyAccrualPayments
|
100000 | |
| CY2017Q1 | cdna |
Description Of Agreement Expected Expiration Year
DescriptionOfAgreementExpectedExpirationYear
|
The agreement will expire at the later of the last-to-expire patent in the EEA or ten years from the first commercial sale of the test in the EEA, which occurred in 2014. | |
| CY2013Q2 | cdna |
Potential Refundable Portion Of Upfront Payment
PotentialRefundablePortionOfUpfrontPayment
|
250000 | |
| CY2013Q2 | cdna |
Potential Refundable Portion Of Upfront Payment
PotentialRefundablePortionOfUpfrontPayment
|
267000 | |
| CY2013Q2 | cdna |
Upfront Payment In Cash
UpfrontPaymentInCash
|
387500 | |
| CY2013Q2 | cdna |
Upfront Payment In Cash
UpfrontPaymentInCash
|
414000 | |
| CY2017Q1 | cdna |
Revenues And Royalties Recognized
RevenuesAndRoyaltiesRecognized
|
0 | |
| CY2016Q1 | cdna |
Revenues And Royalties Recognized
RevenuesAndRoyaltiesRecognized
|
2000 | |
| CY2017Q1 | us-gaap |
Royalty Revenue
RoyaltyRevenue
|
0 | |
| CY2016Q1 | us-gaap |
Royalty Revenue
RoyaltyRevenue
|
96000 | |
| CY2017Q1 | cdna |
Royalty Revenue Receivable
RoyaltyRevenueReceivable
|
0 | |
| CY2016Q4 | cdna |
Royalty Revenue Receivable
RoyaltyRevenueReceivable
|
0 | |
| CY2015Q1 | us-gaap |
Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
|
20000000 | |
| CY2017Q1 | us-gaap |
Loans Payable To Bank Current
LoansPayableToBankCurrent
|
0 | |
| CY2016Q4 | us-gaap |
Loans Payable To Bank Current
LoansPayableToBankCurrent
|
12600000 | |
| CY2017Q1 | us-gaap |
Repayments Of Debt
RepaymentsOfDebt
|
11200000 | |
| CY2017Q1 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
200000 | |
| CY2017Q1 | us-gaap |
Debt Instrument Description
DebtInstrumentDescription
|
The Company agreed to issue to the Lender warrants to purchase shares of the Company’s common stock upon the drawdown of each advance in an amount equal to 1.5% of the amount drawn, divided by the exercise price per share for that tranche. | |
| CY2015Q1 | cdna |
Estimated Fair Value Of Warrants
EstimatedFairValueOfWarrants
|
90000 | |
| CY2017Q1 | us-gaap |
Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
|
800000 | |
| CY2016Q4 | us-gaap |
Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
|
800000 | |
| CY2017Q1 | cdna |
Long Term Debt Maturities Repayments Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsRemainderOfFiscalYear
|
4076000 | |
| CY2017Q1 | cdna |
Long Term Debt Maturities Repayments In Year Two
LongTermDebtMaturitiesRepaymentsInYearTwo
|
16763000 | |
| CY2017Q1 | cdna |
Long Term Debt Maturities Repayments In Year Three
LongTermDebtMaturitiesRepaymentsInYearThree
|
11250000 | |
| CY2017Q1 | cdna |
Long Term Debt Maturities Repayments In Year Four
LongTermDebtMaturitiesRepaymentsInYearFour
|
7155000 | |
| CY2017Q1 | cdna |
Long Term Debt Maturities Repayments
LongTermDebtMaturitiesRepayments
|
39244000 | |
| CY2017Q1 | us-gaap |
Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
|
6858000 | |
| CY2017Q1 | us-gaap |
Long Term Debt
LongTermDebt
|
32386000 | |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
|
0 | |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
250100 | |
| CY2016Q2 | cdna |
Common Stock Purchase Price
CommonStockPurchasePrice
|
3.99 | |
| CY2016Q2 | us-gaap |
Fees And Commissions Transfer Agent
FeesAndCommissionsTransferAgent
|
1800000 | |
| cdna |
Additional Issued Units
AdditionalIssuedUnits
|
334169 | ||
| CY2016Q2 | us-gaap |
Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
|
1700000 | |
| CY2016Q2 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
1002507 | |
| CY2017Q1 | cdna |
Estimated Fair Value Of Warrant Liability Remeasurement Charge
EstimatedFairValueOfWarrantLiabilityRemeasurementCharge
|
3000000 | |
| CY2016Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
365074 | |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
|
357075 | |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
|
8157 | |
| CY2017Q1 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
0 | |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
26668 | |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
|
26140 | |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
329300 | |
| CY2016Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1792286 | |
| CY2017Q1 | cdna |
Share Based Compensation Arrangement By Share Based Payment Award Options Assumed From Acquisitions In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedFromAcquisitionsInPeriod
|
0 | |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1989578 | |
| CY2016Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
6.15 | |
| CY2017Q1 | cdna |
Share Based Compensation Arrangement By Share Based Payment Award Weighted Average Exercised Price Shares Reserved
ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageExercisedPriceSharesReserved
|
0 | |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
2.33 | |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
0 | |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
8.63 | |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
|
6.75 | |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
5.62 | |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
0 | |
| CY2017Q1 | cdna |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber
|
1091452 | |
| CY2017Q1 | cdna |
Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber
|
789964 | |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
1881416 | |
| CY2017Q1 | cdna |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice
|
6.01 | |
| CY2017Q1 | cdna |
Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice
|
5.17 | |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
5.66 | |
| CY2017Q1 | cdna |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm
|
P6Y6M15D | |
| CY2017Q1 | cdna |
Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageRemainingContractualTerm
|
P8Y10M6D | |
| CY2017Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P7Y6M4D | |
| CY2017Q1 | cdna |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue
|
165000 | |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
|
165000 | |
| CY2017Q1 | us-gaap |
Share Price
SharePrice
|
1.40 | |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
1.20 | |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
2.07 | |
| CY2017Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
|
400000 | |
| CY2017Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
1800000 | |
| CY2017Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P2Y3M26D | |
| CY2017Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
391000 | |
| CY2016Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
446000 | |
| CY2017Q1 | us-gaap |
Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
|
0 | |
| CY2017Q1 | us-gaap |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
|
0 | |
| CY2017Q1 | cdna |
Intersegment Sales
IntersegmentSales
|
0 |
